Get the Stockscreener App
4.205
4.08%
0.165
After Hours:
4.21
0.005
+0.12%
Minerva Neurosciences Inc stock is traded at $4.205, with a volume of 168.09K.
It is up +4.08% in the last 24 hours and down -3.78% over the past month.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
See More
Previous Close:
$4.04
Open:
$4.09
24h Volume:
168.09K
Relative Volume:
0.78
Market Cap:
$195.91M
Revenue:
-
Net Income/Loss:
$-293.42M
P/E Ratio:
-0.1442
EPS:
-29.1639
Net Cash Flow:
$-14.87M
1W Performance:
-3.78%
1M Performance:
-3.78%
6M Performance:
-3.33%
1Y Performance:
+97.42%
1-Day Range:
$3.95
$4.275
1-Week Range:
$3.95
$4.68
52-Week Range:
$1.76
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
4.205 | 188.22M | 0 | -293.42M | -14.87M | -29.16 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citizens | Mkt Outperform |
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Minerva Neurosciences Inc (NERV) Cash Flow - TradingKey
Minerva Neurosciences Inc (NERV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Minerva Neurosciences Inc (NERV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Minerva Neurosciences Inc (NERV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NERV|Minerva Neurosciences Inc|Price:4.040|Chg%:-0.410 - TradingKey
Minerva Neurosciences Inc Revenue Breakdown – FWB:4MNA - TradingView
NERV Options Chain — NASDAQ:NERV - TradingView
NERV Options Volatility — NASDAQ:NERV - TradingView
ETFs Investing in Minerva Neurosciences Inc Stocks - TradingView
FEDERATED HERMES, INC. Acquires Additional Shares in Minerva Neu - GuruFocus
Federated Hermes reports 17.17% stake in Minerva (NASDAQ: NERV) - Stock Titan
Minerva Neurosciences (NERV) Slides 3.15% as Stock Tests Key Support at $4.52Iron Condor Alert - dars.gov.et
NERVMinerva Neurosciences Inc Options - Finviz
NERV News | MINERVA NEUROSCIENCES INC (NASDAQ:NERV) - ChartMill
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Value Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Value Benchmark Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2000 Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 3000E Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell Microcap Index - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell 3000E Growth Benchmark - marketscreener.com
Minerva Neurosciences, Inc.(NasdaqCM: NERV) added to Russell 2500 Value Benchmark - marketscreener.com
Price to sales forward of Minerva Neurosciences, Inc – NASDAQ:NERV - TradingView
Minerva Neurosciences, Inc.(NasdaqCM:NERV) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Minerva Neurosciences Inc Actuals & Estimates (NASDAQ:NERV) - TradingView
NERV Forecast — Price Target — Prediction for 2027 - TradingView
Minerva Neurosciences Inc Actuals & Estimates (SWB:4MNA) - TradingView
Minerva Neurosciences Inc Actuals & Estimates (FWB:4MNA) - TradingView
Minerva Neurosciences Inc Actuals & Estimates (BOATS:NERV) - TradingView
Minerva Neurosciences Inc (NERV) Valuation: PE, PB & Fair Value Analysis - TradingKey
4MNA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Minerva Neurosciences, Inc – NASDAQ:NERV - TradingView
Price to book forward of Minerva Neurosciences, Inc – NASDAQ:NERV - TradingView
Minerva Neurosciences Inc (NERV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Minerva Neurosciences Inc (NERV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Minerva Neurosciences Inc (NERV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Minerva Neurosciences Inc (NERV) Institutional Confidence - TradingKey
Minerva Neurosciences Inc (NERV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Minerva Neurosciences (NERV) Holds Near Support After Modest Decline: Key Levels in FocusMutual Fund Flow - newsline.com
Minerva Neurosciences (NERV) CFO awarded 680,000 stock options at $4.6800 - Stock Titan
Minerva Neurosciences (NERV) CEO granted 1.69M stock options at $4.68 strike - Stock Titan
Minerva Neurosciences (NERV) grants director 50,000 stock options at $4.68 - Stock Titan
Minerva Neurosciences (NERV) director receives stock options for 50,000 shares - Stock Titan
Minerva Neurosciences grants 50,000 options to director | NERV Insider Trading - Stock Titan
Minerva Neurosciences director granted 50,000 options | NERV Insider Trading - Stock Titan
Minerva Neurosciences (NERV) awards 50,000 stock options to director - Stock Titan
Minerva Neurosciences (NERV) loses 37.5% in 4 weeks, here's why a trend reversal may be around the corner - MSN
NERV: Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027 - TradingView
Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting - TipRanks
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):